Helen of Troy: $885M Impaired, +70% in a Month

Helen of Troy (HELE, ≈$570M cap) is a consumer products holdco — Home & Outdoor (OXO, Hydro Flask, Osprey) plus Beauty & Wellness (Drybar, Curlsmith, Olive & June, Vicks/Honeywell/PUR). The FY2026 10-K filed April 23, 2026 crystallized five years of deterioration. We're looking now because the filing's bear math is in direct conflict with a +70% one-month rip that has the stock at RSI 90.4.

What the filing says

Fiscal year ended February 28, 2026:

• Revenue $1,786.3M, fifth consecutive annual decline (from $2.22B FY2022). Reported -6.4%; organic -12.2% after stripping the Olive & June acquisition contribution.
• $885.9M goodwill + intangible impairments in a single year. Hydro Flask goodwill zero, Drybar zero, Curlsmith near-zero, Health & Wellness $235.2M, Osprey $113.1M. Cumulative FY2025-FY2026 impairments: $937.4M.
• Net loss ≈$899M. Stockholders' equity collapsed $1.68B → $798M.
• Tariff COGS drag $50.7M (2.8% of revenue). China sourcing still 57% of finished goods (peers SN, NWL, YETI, HBB at 10-30%).
• Debt $785.5M, all maturing February 15, 2029 as a bullet. $91.1M covenant headroom. Revolver cut $1.0B → $750M in Nov 2025 amendment. Max leverage covenant steps 4.50x → 4.00x at November 30, 2026.
• New CEO Scott Uzzell (Aug 2025). Eight months in: no named transformation program, zero forward guidance, no quantified margin targets.
• Every quarter of FY2026 triggered quantitative impairment testing; management revised forecasts down in each. OXO and Osprey reporting units sit at 104% fair value coverage (DCF value barely exceeds carrying value) — a 10% further revenue decline triggers another impairment wave.
• The 10-K reflects China tariffs at ≈20% IEEPA. The April 2026 escalation to 145% is post-filing and not modeled anywhere.

What the market thinks

HELE $23.62 (Apr 26, 2026). RSI 90.4. +70.2% in one month. Short interest 21.5%. Beta 0.86, idiosyncratic variance 67% — sector beta is meaningful, which matters for vehicle selection.

Options, Jan 2027 expiry (263d):

• OI P/C 1.98 (puts 2x calls). $18 strike puts: 3,192 OI.
• Today's call volume concentrated at $30 strike (5,106 vs 532 OI = 9.6x — takeover speculation).
• Market-implied P(HELE < $17.50, -25%) = ≈20%; P(< $12.50, -50%) = ≈9%.

Filing-implied probability of -25% within 12 months is ≈50-55% (factor decomposition stacking tariff differential, SN displacement, impairment cascade continuation, covenant trip). Gap: ≈30 percentage points.

Why the gap exists

• HELE is mid-cap with ≈6 sell-side analysts. Undercovered relative to consumer megacaps.
• The bear case requires synthesizing 5-6 peer 10-Qs (NWL, SN, HBB, YETI, SPB, CENTA) to see that HELE is the failing name in a cohort that's coping with the same factors.
• The squeeze is real and dominant: 21.5% short interest covering into a +70% rip means current price formation is mechanics, not fundamentals.
• Activist/takeover speculation is the bullish narrative crowding out the bear math. Today's call volume concentrated at the $30 strike (9.6x OI ratio) is the tell.
• Nov 30, 2026 covenant step-down is seven months out — outside most analyst earnings models.

Risks (ranked by impact)

1. Activist 13D or strategic review announcement (P≈25-30%). Retraces toward $32-38 SOTP on OXO carve-out math. Donerail/HZO is the recent comp.
2. Refi at par before Nov 2026 step-down (P≈15%). Covenant factor zeros; removes ≈20% of bear case weight.
3. Uzzell delivers credible plan at June Q1 print (P≈15%). Sentiment shift; fundamentals get re-rated to base case.
4. SN guidance miss on beauty (P≈10%). Kills the long leg of the pair structure.
5. Section 232 housewares carve-out / accelerated Vietnam ramp (P≈10%). Tariff differential factor compresses.

Catalysts

• ~May 6-8, 2026: SN Q1 earnings — confirms continued beauty share migration
• ~July 2026: HELE Q1 FY2027 print — first post-tariff-escalation quarter; covenant ratio update; Uzzell strategy reveal
• Aug 31, 2026: Q2 FY27 covenant test at 4.50x
• Nov 9, 2026: Section 301 COVID-era exclusions cliff
• Nov 30, 2026: Covenant step-down 4.50x → 4.00x
• Feb 15, 2029: $735.5M debt bullet maturity

What would change our mind

• 13D filed by an operational activist with named OXO carve-out plan
• Strategic alternatives announcement (sale process, segment divestiture)
• Refi achieved at <8% before Nov 2026 step-down
• HELE Q1 FY2027 revenue ≥0% YoY (vs current trajectory -8% to -12%)
• Uzzell announces a quantified cost program (>5% of revenue) with margin targets
• China sourcing drops below 30% via accelerated diversification
• SN beauty growth decelerates to <15% YoY (kills pair leg structurally, not just cyclically)

A note on vehicle

The thesis and the vehicle are not the same problem. Naked equity short into 21.5% SI, RSI 90, and active takeover speculation means squeeze mechanics dominate fundamental edge in the near term — the bear can be right and lose money before being paid. A long SN / short HELE pair (beta-adjusted) sterilizes the squeeze asymmetrically because SN's tape is fundamentally supported by its own results. Aug 2026 $20/$15 put spreads (≈$1.35 cost) capture the July Q1 print and the August covenant test with defined downside.

Evidence